<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04686253</url>
  </required_header>
  <id_info>
    <org_study_id>2020-6</org_study_id>
    <nct_id>NCT04686253</nct_id>
  </id_info>
  <brief_title>Internal Microstructure of Patent Foramen Ovale Related to Stroke</brief_title>
  <acronym>IMPORT</acronym>
  <official_title>Internal Microstructure of Patent Foramen Ovale Related to Cryptogenic Stroke, Transient Ischemic Attack or Migraine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>China National Center for Cardiovascular Diseases</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>China National Center for Cardiovascular Diseases</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to (1) investigate the internal microstructure of patent foramen ovale&#xD;
      related to cryptogenic stroke, transient ischemic attack or migraine and determine the&#xD;
      effectiveness of transcatheter closure in these patients; (2) evaluate the microstructural&#xD;
      features of asymptomatic patients with PFO and make a follow-up.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patent foramen ovale (PFO) is associated with a variety of pathological conditions, and it is&#xD;
      presumed to be related to the occurrence of cryptogenic stroke (CS), transient ischemic&#xD;
      attack (TIA) or migraine. In addition, the main hypothesized pathophysiologic mechanism is&#xD;
      paradoxical embolization, namely microemboli or metabolites from the venous circulation to&#xD;
      enter the systemic circulation. The morphological characteristics of PFO have the potential&#xD;
      to predict risks and screen the appropriate candidates for transcatheter closure. The&#xD;
      structure features for predicting risk included atrial septal aneurysm, a large right-left&#xD;
      shunt, long-tunnel PFO and so on. However, the in-vivo internal microstructure of PFO is&#xD;
      still unclear. The microstructural features might provide important information for better&#xD;
      understanding the PFO and risk stratification.&#xD;
&#xD;
      The aim of this study is to (1) investigate the internal microstructure of patent foramen&#xD;
      ovale related to cryptogenic stroke, transient ischemic attack or migraine and determine the&#xD;
      effectiveness of transcatheter closure in these patients; (2) evaluate the microstructural&#xD;
      features of asymptomatic patients with PFO and make a follow-up.&#xD;
&#xD;
      This study will enroll subjects with PFO, and enrollment will be divided into three phases.&#xD;
&#xD;
      Phase 1: PFO patients with CS or/and TIA (transcatheter closure of PFO was performed). A&#xD;
      minimum of 100 patients is reached.&#xD;
&#xD;
      Phase 2: PFO patients with migraine (transcatheter closure of PFO was performed). A minimum&#xD;
      of 100 patients is reached.&#xD;
&#xD;
      Phase 3: PFO patients without symptom (5-year follow-up). A minimum of 100 patients is&#xD;
      reached.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 23, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2025</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>Adverse Events after evaluation of PFO internal microstructure</measure>
    <time_frame>5 years</time_frame>
    <description>cryptogenic stroke, transient ischemic attack , migraine or systemic embolism</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Patent Foramen Ovale</condition>
  <arm_group>
    <arm_group_label>PFO patients with CS or/and TIA</arm_group_label>
    <description>PFO patients with CS or/and TIA (transcatheter closure of PFO was performed).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PFO patients with migraine</arm_group_label>
    <description>PFO patients with migraine (transcatheter closure of PFO was performed).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PFO patients without symptom</arm_group_label>
    <description>PFO patients without symptom (5-year follow-up).</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>not appliable</intervention_name>
    <description>not appliable</description>
    <arm_group_label>PFO patients with CS or/and TIA</arm_group_label>
    <arm_group_label>PFO patients with migraine</arm_group_label>
    <arm_group_label>PFO patients without symptom</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        This study will enroll subjects with PFO, and enrollment will be divided into three&#xD;
        cohorts.&#xD;
&#xD;
        Cohort 1: PFO patients with CS or/and TIA (transcatheter closure of PFO was performed). A&#xD;
        minimum of 100 patients is reached.&#xD;
&#xD;
        Cohort 2: PFO patients with migraine (transcatheter closure of PFO was performed). A&#xD;
        minimum of 100 patients is reached.&#xD;
&#xD;
        Cohort 3: PFO patients without symptom (5-year follow-up). A minimum of 100 patients is&#xD;
        reached.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients aged 16 to 65 years without any known vascular risk factor, including&#xD;
             hypertension, hypercholesterolemia, diabetes mellitus, atrial fibrillation, smoking&#xD;
             and obesity;&#xD;
&#xD;
          2. Documented PFO with right-to-left shunt â‰¥ 20 micro-bubbles by c-TCD;&#xD;
&#xD;
          3. Stroke group: history of ischemic stroke (based on brain magnetic resonance imaging)&#xD;
             or TIA within 6 months without other identifiable causes (Phase1);&#xD;
&#xD;
          4. Migraine group: history of migraine headaches more than one year without other&#xD;
             identifiable causes (Phase2);&#xD;
&#xD;
          5. Control group: incidental finding of PFO without neurological or systemic symptoms&#xD;
             (Phase3).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any identifiable cause of ischemic stroke/TIA or migraine other than PFO;&#xD;
&#xD;
          2. History of stroke or TIA within the past one month;&#xD;
&#xD;
          3. Presence of cardiac enlargement or dysfunction;&#xD;
&#xD;
          4. Presence of coexisting cardiovascular structural malformations/diseases;&#xD;
&#xD;
          5. Presence of carotid artery lesions or coronary artery disease;&#xD;
&#xD;
          6. Presence of deep vein thrombosis or pulmonary embolism;&#xD;
&#xD;
          7. Presence of implanted cardiac devices;&#xD;
&#xD;
          8. Evidence of hypercoagulable state;&#xD;
&#xD;
          9. Allergic to contrast medium;&#xD;
&#xD;
         10. Echocardiographic evidence of intra-cardiac thrombus, mass, tumor or vegetation;&#xD;
&#xD;
         11. Active endocarditis or other infections.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Chaowu Yan, PhD and MD</last_name>
    <phone>+861088398408</phone>
    <email>chaowuyan@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chaowu Yan</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100037</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chaowu Yan, PhD and MD</last_name>
      <phone>+861088398408</phone>
      <email>chaowuyan@163.com</email>
    </contact>
    <investigator>
      <last_name>Chaowu Yan, PhD and MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences,Fuwai Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100037</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chaowu Yan, PhD and MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 23, 2020</study_first_submitted>
  <study_first_submitted_qc>December 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 28, 2020</study_first_posted>
  <last_update_submitted>April 16, 2021</last_update_submitted>
  <last_update_submitted_qc>April 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>patent foramen ovale</keyword>
  <keyword>stroke</keyword>
  <keyword>transient ischemic attack</keyword>
  <keyword>migraine</keyword>
  <keyword>microstructure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Foramen Ovale, Patent</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

